Potential clinical application of LCZ696 in patients with chronic heart failure in real life clinical practice: results from TREAT HF Study

Back

ESC Premium Access

Potential clinical application of LCZ696 in patients with chronic heart failure in real life clinical practice: results from TREAT HF Study

Session: Pharmacologic approaches in HF: could we do better?

Topic: Heart failure, other

Speaker: Professor Y. Cavusoglu (Eskisehir, TR)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Yuksel Cavusoglu

Eskisehir Osmangazi University, Eskisehir (Türkiye)

1 presentation

0 follower

9 more presentations in this session

The risk of atrial fibrillation with ivabradine treatment: A meta-analysis with trial sequential analysis of over 40000 patients

Speaker: Associate Professor I. Tanboga (Istanbul, TR)

Differential impacts of digoxin modulated by volume status on one-year mortality in patients with acute heart failure

Speaker: Doctor W. Wang (Taipei, TW)

Dosage-dependent association between betablocker therapy with Carvedilol or Metoprolol and the risk of appropriate ICD therapy in primary prevention ICD patients.

Speaker: Doctor A. Huth Ruwald (Copenhagen, DK)

The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway

Access

Slides

Video

Effect of in-hospital treatment on short-term mortality of elderly versus non-elderly patients hospitalized for acute heart failure

Speaker: Doctor S. Katsanos (Athens, GR)

Access

Abstract

Access the full session

Pharmacologic approaches in HF: could we do better?

Speakers: Professor Y. Cavusoglu, Associate Professor I. Tanboga, Doctor W. Wang, Doctor A. Huth Ruwald, Doctor S. Katsanos

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources